Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12592953 | 1.00 | CFTR (0.50) | CFTRHDAC3HDAC1HDAC2ADORA2A | |
| SCHEMBL12592888 | 0.85 | HDAC3 (0.46) | CFTRHDAC3HDAC1HDAC2ADORA2A | |
| SCHEMBL1761083 | 0.85 | HDAC3 (0.46) | CFTRHDAC3HDAC1HDAC2ADORA2A | |
| SCHEMBL1760898 | 0.85 | HDAC3 (0.46) | CFTRHDAC3HDAC1HDAC2ADORA2A | |
| SCHEMBL12592956 | 0.82 | ADORA2A (0.50) | HDAC1HDAC2ADORA2AADORA1ADORA2B | |
| SCHEMBL1760842 | 0.82 | ADORA2A (0.50) | HDAC1HDAC2ADORA2AADORA1ADORA2B | |
| SCHEMBL1760880 | 0.80 | NAMPT (0.42) | CFTRHDAC3HDAC1HDAC2ADORA2A | |
| SCHEMBL12592960 | 0.76 | ADORA2A (0.40) | ADORA2AADORA1ADORA2B | |
| SCHEMBL1761044 | 0.76 | ADORA2A (0.40) | ADORA2AADORA1ADORA2B | |
| SCHEMBL4049256 | 0.73 | PIK3CD (0.41) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | CFTR 83/4885HDAC3 3905/4885HDAC1 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.